(II)



wherein A^1, A^2 and A^3, X and the active agent are as defined in claim **1**.

30-33. (canceled)

34. An agent-linker compound comprising a linker and an active agent, wherein the linker comprises the moiety of formula (II):

(II)



wherein A^1, A^2 and A^3 and the active agent are as defined in claim **1**,

wherein X is N and there are two active agents, each attached to X via a linker.

35-38. (canceled)

39. A compound of formula (Ia):

(Ia)



wherein:

A^1, A^2, A^3, and X are as defined in claim **1**;



Q^1 is

where a1=0 to 5, b1=0 to 16, c1=0 to 5, d1 is 0 to 16, and b1+d1=0 to 16, and Y^L is a functional linking moiety; and

Y is a group capable reacting with another moiety to form Y^L.

40. A compound according to claim **39**, wherein Y is selected from the group consisting of:

(a) —C≡CH;

(b) —C(═O)OH;

(c) —N_3; and

(d) —NH_2.

41. (canceled)

42. A compound of formula (Ic):

(Ic)



wherein:

A^1, A^2 and A^3 are as defined in claim **1**;

X^1 is selected from NH_2, OH and SH.

43. A pharmaceutical composition comprising, a conjugate according to claim **1**, and a carrier, excipient or diluent.

44. (canceled)

45. A method of treating a proliferative disease comprising administering a therapeutically effective amount of a conjugate according to claim **10** to a patient in need thereof.

* * * * *